Puma Biotech (PBYI) Misses Q4 EPS by 12c; Offers Guidance

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.07), $0.12 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $53.7 million versus the consensus estimate of $57.06 million.

GUIDANCE:

Puma Biotech sees Q1 2023 revenue of $43-46 million, versus the consensus of $51 million.

Puma Biotech sees FY2023 revenue of $205-210 million, versus the consensus of $227.4 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FuelCell Energy signs deal with Fit Energy for up to 380 MW of power
• KB Home (KBH) PT Raised to $66 at UBS on Market Stabilisation and Execution